Immunocore Holdings plc (NASDAQ:IMCR) Shares Acquired by BIT Capital GmbH

BIT Capital GmbH grew its stake in shares of Immunocore Holdings plc (NASDAQ:IMCR) by 182.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 67,840 shares of the company’s stock after acquiring an additional 43,840 shares during the quarter. BIT Capital GmbH owned about 0.14% of Immunocore worth $2,001,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of IMCR. Primecap Management Co. CA increased its stake in Immunocore by 8.0% during the 4th quarter. Primecap Management Co. CA now owns 2,668,550 shares of the company’s stock valued at $78,722,000 after purchasing an additional 196,530 shares in the last quarter. Assetmark Inc. grew its holdings in shares of Immunocore by 5.3% during the fourth quarter. Assetmark Inc. now owns 32,171 shares of the company’s stock valued at $949,000 after buying an additional 1,616 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Immunocore by 12.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company’s stock valued at $248,000 after acquiring an additional 960 shares during the period. Crossmark Global Holdings Inc. raised its stake in Immunocore by 36.7% in the 4th quarter. Crossmark Global Holdings Inc. now owns 38,020 shares of the company’s stock worth $1,121,000 after acquiring an additional 10,217 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. lifted its position in Immunocore by 125.4% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 49,608 shares of the company’s stock worth $1,463,000 after acquiring an additional 27,598 shares during the period. 84.50% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on IMCR shares. HC Wainwright reissued a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a report on Wednesday, March 12th. Needham & Company LLC reissued a “buy” rating and set a $71.00 target price on shares of Immunocore in a report on Wednesday, March 12th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $35.00 price target on shares of Immunocore in a report on Friday, March 7th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $65.64.

Immunocore Price Performance

IMCR stock opened at $29.47 on Thursday. Immunocore Holdings plc has a 52-week low of $27.19 and a 52-week high of $66.00. The business has a fifty day moving average of $30.00 and a two-hundred day moving average of $31.01. The stock has a market cap of $1.47 billion, a price-to-earnings ratio of -31.02 and a beta of 0.79. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03.

Insider Transactions at Immunocore

In related news, Director Bros. Advisors Lp Baker acquired 807,338 shares of the firm’s stock in a transaction dated Monday, March 17th. The shares were purchased at an average cost of $29.72 per share, for a total transaction of $23,994,085.36. Following the acquisition, the director now owns 2,144,060 shares in the company, valued at $63,721,463.20. The trade was a 60.40 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 9.10% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.